Menu
Search
|

Menu

Close
X

ADMA Biologics Inc ADMA.OQ (NASDAQ Stock Exchange Capital Market)

3.86 USD
-0.03 (-0.77%)
As of 2:29 AM IST
chart
Previous Close 3.89
Open 3.88
Volume 9,879
3m Avg Volume 39,865
Today’s High 3.93
Today’s Low 3.79
52 Week High 5.44
52 Week Low 2.02
Shares Outstanding (mil) 25.79
Market Capitalization (mil) 82.28
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.75 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
6
FY16
11
FY15
7
EPS (USD)
FY17
-1.057
FY16
-1.616
FY15
-1.721
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
6.69
5.77
Price to Book (MRQ)
vs sector
2.97
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
117.93
16.52
LT Debt to Equity (MRQ)
vs sector
93.84
12.22
Return on Investment (TTM)
vs sector
-51.15
14.43
Return on Equity (TTM)
vs sector
-154.84
16.13

EXECUTIVE LEADERSHIP

Steven Elms
Chairman of the Board, Since
Salary: --
Bonus: --
Adam Grossman
President, Chief Executive Officer, Director, Since 2011
Salary: $447,591.00
Bonus: $125,000.00
Jerrold Grossman
Vice Chairman of the Board, Since
Salary: --
Bonus: --
Brian Lenz
Chief Financial Officer, Since 2012
Salary: $318,525.00
Bonus: $79,568.00
James Mond
Chief Scientific and Medical Officer, Since 2012
Salary: $323,460.00
Bonus: $53,560.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

C/O Adma Biologics
Inc., 465 State Route 17
RAMSEY   NJ   07446

Phone: +1201.4785552

ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.

SPONSORED STORIES